Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.30 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1301401 | 1.00 | METTL3 (0.54) | METTL3EGFRCFDMRGPRX4PIK3CG | |
| SCHEMBL12108004 | 0.96 | METTL3 (0.54) | METTL3EGFRMRGPRX4 | |
| SCHEMBL12108019 | 0.96 | METTL3 (0.54) | METTL3EGFRMRGPRX4 | |
| SCHEMBL1301433 | 0.94 | METTL3 (0.54) | METTL3EGFRCFDMRGPRX4KCNJ5 | |
| SCHEMBL1301430 | 0.94 | METTL3 (0.54) | METTL3EGFRCFDMRGPRX4KCNJ5 | |
| SCHEMBL1300488 | 0.93 | METTL3 (0.53) | METTL3MRGPRX4 | |
| SCHEMBL1300489 | 0.93 | METTL3 (0.53) | METTL3MRGPRX4 | |
| SCHEMBL12108014 | 0.93 | METTL3 (0.52) | METTL3MRGPRX4 | |
| SCHEMBL1301011 | 0.92 | METTL3 (0.54) | METTL3EGFRMRGPRX4PIK3CG | |
| SCHEMBL1301007 | 0.92 | METTL3 (0.54) | METTL3EGFRMRGPRX4PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | claimed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | claimed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885EGFR 4552/4885CFD 4253/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885EGFR 4552/4885CFD 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.